Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.

[1]  R. Mirimanoff,et al.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial , 2015, The Lancet.

[2]  V. Rusch,et al.  Role of induction therapy: surgical resection of non-small cell lung cancer after induction therapy. , 2013, Thoracic surgery clinics.

[3]  C. Ramos‐Font,et al.  Is FDG‐PET suitable for evaluating neoadjuvant therapy in non‐small cell lung cancer? Evidence with systematic review of the literature , 2010, Journal of surgical oncology.

[4]  Yang Liu,et al.  Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  F. Detterbeck,et al.  A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[7]  N. Willich,et al.  Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. , 2008, The Lancet. Oncology.

[8]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  G. Giaccone,et al.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[10]  W. Richards,et al.  Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non‐small cell lung cancer in CALGB protocol #8935 , 2006, Journal of surgical oncology.

[11]  K. Nackaerts,et al.  Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lu , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Stupp,et al.  Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study , 2006, British Journal of Cancer.

[13]  Otto S Hoekstra,et al.  Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Kris,et al.  Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. , 2002, Journal of Clinical Oncology.

[15]  J. Roth,et al.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1998, Lung cancer.

[16]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Sugarbaker,et al.  Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. , 1995, The Journal of thoracic and cardiovascular surgery.

[18]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[19]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[20]  M. Kris,et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.

[21]  N. Altorki,et al.  Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. , 2011, The Journal of thoracic and cardiovascular surgery.

[22]  P. V. Van Schil,et al.  Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. , 2007, Journal of Thoracic Oncology.

[23]  N. Altorki,et al.  Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. , 2004, The Annals of thoracic surgery.

[24]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .